Skip to main content

Market Overview

Inhibikase Initiates Early-Stage Study Of Parkinson's Candidate

  • Inhibikase Therapeutics Inc (NASDAQ: IKT) has dosed the first patients in its Phase 1 trial of IkT-148009, an Abelson Tyrosine Kinase (c-Abl) inhibitor, for the treatment of Parkinson's disease.
  • This randomized Phase 1 study in healthy volunteers will assess the safety, tolerability, and pharmacokinetics (PK) of IkT-148009 to identify the maximum tolerated dose in single and multiple ascending dose settings.
  • In preclinical animal models, the drug candidate demonstrated that once a day, oral therapy with IkT-148009 can halt and reverse the functional loss in the brain and gastrointestinal tract.
  • Activation of c-Abl, drives biochemical pathways and processes that lead to degradation of the neurons affected in Parkinson's disease. Inhibition of c-Abl may restore functional loss for neurons that have not fully degraded in the brain and remodel neurons in the gastrointestinal tract, two major organ systems affected by the disease.
  • Price Action: IKT gained 9.5% at $7.72 in the market trading hours on the last check Wednesday.

Related Articles (IKT)

View Comments and Join the Discussion!

Posted-In: Parkinson’s Disease Phase 1 TrialBiotech News FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at